Literature DB >> 15944292

Glucocorticoid-induced TNF receptor functions as a costimulatory receptor that promotes survival in early phases of T cell activation.

Edward M Esparza1, Robert H Arch.   

Abstract

Glucocorticoid-induced TNFR (GITR) is a member of the TNFR family that can inhibit the suppressive function of regulatory T cells and promote the survival and activation of T cells. However, little is known about the molecular mechanisms regulating T cell survival and activation downstream of GITR. To gain further insight into the cellular events and signaling pathways triggered by GITR, survival, proliferation, and cytokine production as well as activation of MAPKs and NF-kappaB were monitored after cross-linking of the receptor on naive and activated T cells. GITR cross-linking provided costimulation of naive and activated T cells and resulted in activation of MAPKs and NF-kappaB. Although GITR-induced signaling pathways augmented the survival of naive T cells, they were not sufficient to inhibit activation-induced cell death triggered by CD3 cross-linking of activated T cells. Differences in the contributions of GITR to cell survival between naive and activated T cells suggest that the receptor triggers specific pathways depending on the activation state of the T cell.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15944292     DOI: 10.4049/jimmunol.174.12.7869

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.

Authors:  C Ritchlin; F Tausk
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

Review 2.  Enhancing versus suppressive effects of stress on immune function: implications for immunoprotection and immunopathology.

Authors:  Firdaus S Dhabhar
Journal:  Neuroimmunomodulation       Date:  2009-06-29       Impact factor: 2.492

3.  Anti-GITR therapy promotes immunity against malignant glioma in a murine model.

Authors:  Jason Miska; Aida Rashidi; Alan L Chang; Megan E Muroski; Yu Han; Lingjiao Zhang; Maciej S Lesniak
Journal:  Cancer Immunol Immunother       Date:  2016-10-12       Impact factor: 6.968

Review 4.  Modulation of GITR for cancer immunotherapy.

Authors:  David A Schaer; Judith T Murphy; Jedd D Wolchok
Journal:  Curr Opin Immunol       Date:  2012-01-12       Impact factor: 7.486

5.  Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine.

Authors:  Spyros Aslanidis; Athina Pyrpasopoulou; Stella Douma; Areti Triantafyllou
Journal:  Clin Rheumatol       Date:  2007-11-10       Impact factor: 2.980

6.  Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Authors:  Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 7.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

8.  Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation.

Authors:  Adam D Cohen; David A Schaer; Cailian Liu; Yanyun Li; Daniel Hirschhorn-Cymmerman; Soo Chong Kim; Adi Diab; Gabrielle Rizzuto; Fei Duan; Miguel A Perales; Taha Merghoub; Alan N Houghton; Jedd D Wolchok
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

9.  Glucocorticoid-induced tumor necrosis factor receptor negatively regulates activation of human primary natural killer (NK) cells by blocking proliferative signals and increasing NK cell apoptosis.

Authors:  Baoying Liu; Zhuqing Li; Sankaranarayana P Mahesh; Seth Pantanelli; Frank S Hwang; Willie O Siu; Robert B Nussenblatt
Journal:  J Biol Chem       Date:  2008-01-29       Impact factor: 5.157

10.  Key role of the GITR/GITRLigand pathway in the development of murine autoimmune diabetes: a potential therapeutic target.

Authors:  Sylvaine You; Lynn Poulton; Steve Cobbold; Chih-Pin Liu; Michael Rosenzweig; Douglas Ringler; Wen-Hui Lee; Berta Segovia; Jean-François Bach; Herman Waldmann; Lucienne Chatenoud
Journal:  PLoS One       Date:  2009-11-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.